Heart Disease
Cleerly Secures $192M for Heart Attack-Predicting AI Technology
Cleerly, AI, Heart Disease, Coronary Artery Scanning, Funding
Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels
Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease
Edgewise Therapeutics Sees 50% Stock Surge Following Positive Safety Data for Heart Disease Drug EDG-7500
Edgewise Therapeutics, EDG-7500, Heart Disease, Cardiomyopathy, Stock Surge, Safety Data, Camzyos Rival